Advances in understanding the ways in which the immune system fails to control tumor
growth or prevent autoimmunity have led to the development of powerful therapeutic …

Targeted agents are increasingly used for the therapy of acute myeloid leukemia (AML).
Gemtuzumab ozogamicin (GO) is the first antibody-drug conjugate (ADC) approved for …

Objective To provide an overview of acute leukemia, comparing incidence, presenting
symptoms, diagnosis, prognosis, and treatment of the major subtypes. Data Sources Review …

Introduction Traditional cancer therapy has many disadvantages such as low selectivity and
high toxicity of chemotherapy, as well as insufficient efficacy of targeted therapy. To enhance …

Antibody‐drug conjugates (ADC s) combine highly specific monoclonal antibodies with
potent cytotoxic drugs. Their synergy allows for targeted delivery of toxic drugs to cancer …

Optimization of the salvage regimen is required to improve prognosis in primary refractory or
relapsed acute myeloid leukemia (AML). In fit patients, a bridge to allogeneic transplant is …

We retrospectively evaluated the clinical efficacy and toxicity of gemtuzumab ozogamicin
(GO) in patients with relapsed acute myeloid leukemia (AML). Nineteen patients (median 70 …

Outcome of patients with primary refractory/relapsed (R/R) acute myeloid leukemia (AML)
remains dismal. Herein, we present a retrospective monocentric study of 24 very high-risk …

Background More than one-third of patients with acute myeloid leukemia (AML) will relapse
after allogenic hematopoietic cell transplant (allo-HCT). The main challenge is to overcome …

Ninety-four adults with newly diagnosed or relapsed/refractory acute myeloid leukemia
(AML) were treated with fractionated doses of gemtuzumab ozogamicin (GO) at one-single …